JAB-3312 Activity in Adult Patients With Advanced Solid Tumors

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jacobio Pharmaceuticals Co., Ltd.
• Collaborator: AbbVie
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

• Written informed consent, according to local guidelines, signed and dated by the participant prior to the performance of any study-specific procedures, sampling, or analyses.

• Participant must be ≥18 years of age at the time of signature of the informed consent form (ICF).

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

• Sufficient organ function

• Participants with a life expectancy ≥3 months

• Participants must have at least 1 measurable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

Exclusion Criteria:

• History of cancer that is histologically distinct from the cancers under study

• Brain or spinal metastases

• History of severe autoimmune disease or autoimmune disorder that requires chronic systemic corticosteroid treatment.

• Has active hepatitis B, or hepatitis C infection